Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 128

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 128
---
 material changes in the final data.

From time to
time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical studies, which is based on a preliminary
analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive
review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part
of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the
top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations
may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and
verification procedures that may result in the final data being materially different from the preliminary data we previously published.
As a result, top-line data should be viewed with caution until the final data are available.

From time to time, we may also disclose
interim data from our preclinical studies and clinical studies. Interim data from clinical studies that we may complete are subject to
the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become
available or as patients from our clinical studies continue other treatments for their disease. Adverse differences between preliminary,
interim or final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors
could result in volatility in the price of our common stock after this transaction.

Further, others,
including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret
or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general If the interim, top-line, or preliminary data that we report
differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain
approval or certification for, and commercialize, our product candidates may be harmed, which could harm our business, operating results,
prospects or financial condition.

Our product candidates
may in the future be associated with serious adverse events, undesirable side effects or have other properties that could halt their clinical
development, prevent their regulatory approval or certification, limit their commercial potential or result in significant negative consequences.

Adverse